戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ) patients more frequently had nystagmus and photophobia.
2 mus, decreased visual acuity, hyperopia, and photophobia.
3 ged from rod-cone to cone-rod dystrophy with photophobia.
4  in mice as a measure of migraine-associated photophobia.
5 ed by ichthyosis follicularis, atrichia, and photophobia.
6  had ocular involvement, with 65% describing photophobia.
7 ement as well as reduction of both glare and photophobia.
8 decreased visual quality marked by glare and photophobia.
9 n body sensation, conjunctival hyperemia and photophobia.
10 rgins and also moderate dry eyes with severe photophobia.
11  for sleep disorders and migraine-associated photophobia.
12 void confounding effects of illumination and photophobia.
13 provide a neural substrate for migraine-type photophobia.
14 g head pain and associated symptoms, such as photophobia.
15 s for migraine and other disorders involving photophobia.
16 ral visual impairment (CVI) often experience photophobia.
17 olors, impaired visual acuity, nystagmus and photophobia.
18 f chronic ocular pain, dry eye symptoms, and photophobia.
19 larly suffered from migraines with auras and photophobia.
20 er, he presented with eye pain, redness, and photophobia.
21  we noted transient headaches (11 patients), photophobia (11 patients), reduction in serum HDL concen
22 58%] of 353 vs 126 [37%] of 342 [p<0.0001]), photophobia (180 [51%] of 353 vs 99 [29%] of 342 [p<0.00
23 ers (60%), pain (44%), severe pain (6%), and photophobia (19%).
24  bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modif
25 symptoms were new onset eye pain (25.7%) and photophobia (22.9%).
26 , with the greatest differences observed for photophobia (70% versus 6%), poor balance (63% versus 4%
27 ache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of naus
28 he and 2 weeks of progressive somnolence and photophobia accompanied by binocular horizontal diplopia
29 ed visual acuity, nystagmus, strabismus, and photophobia, although pigmentation of skin and hair is r
30 ter surgery 12 patients (75.00%) reported no photophobia and 10 patients (62.50%) reported no glare.
31  This behavior appears to be an indicator of photophobia and cannot be fully explained by gross abnor
32                                    Transient photophobia and discomfort were common.
33                                              Photophobia and glare improved in every case except for
34          The other symptoms include tearing, photophobia and leukokoria.
35 , and any pattern of secondary symptoms (eg, photophobia and phonophobia).
36 h baseline and associated with nausea and/or photophobia and phonophobia.
37 ted with complaints of pain, blurred vision, photophobia and redness in her left eye for a month.
38 ying protein 1 (RAMP1), can be a modifier of photophobia and, by extension, suggest that genetic or e
39 acterized by the clinical triad of epiphora, photophobia, and blepharospasm; increased intraocular pr
40 ecessive trait, characterized by low vision, photophobia, and lack of color discrimination.
41 l vision and subsequently night vision, mild photophobia, and moderate to high myopia.
42 ontaneous photopsia, self-light of the eye), photophobia, and nyctalopia (impaired night vision); and
43 ease (IRD) characterized by night blindness, photophobia, and nystagmus, and distinctive electroretin
44  colors, impaired visual acuity in daylight, photophobia, and nystagmus.
45 changes may result in reduced visual acuity, photophobia, and ocular irritation, though these symptom
46 ce, and migraine symptoms, such as headache, photophobia, and phonophobia, is a requisite diagnostic
47 omes were non-inferiority at 2 h for nausea, photophobia, and phonophobia.
48        Non-inferiority was shown for nausea, photophobia, and phonophobia.
49 hyosis, failure to thrive, thrombocytopenia, photophobia, and progressive hearing loss.
50 nful left eye proptosis, purulent discharge, photophobia, and progressive vision loss, which eventual
51 cular pain and discomfort, inflammation, and photophobia, and, if left untreated, can lead to infecti
52 s of episcleritis, while severe eye pain and photophobia are the most frequent onset of anterior uvei
53 arring alopecia, slightly runted growth, and photophobia arose at The Jackson Laboratory in 1993 in t
54  all, mice respond to PACAP in a preclinical photophobia assay.
55 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32
56 eriphery of the mouse to cause migraine-like photophobia by apparently distinct mechanisms.
57        Here, we establish a genetic model of photophobia by engineering increased sensitivity to CGRP
58                  Ocular side effects such as photophobia, cataracts, glaucoma, retinopathy, and other
59 atients' experience with colour and migraine photophobia could originate in cone-driven retinal pathw
60 The clinical phenotype was typical CORD with photophobia, decreased central vision, and dyschromatops
61 olecular targets for selective prevention of photophobia during migraine.
62 ppeared ill and developed ocular discomfort, photophobia, dysuria, and macular rashes on the trunk an
63 body, and choroid-causing eye redness, pain, photophobia, floaters, and blurred vision.
64              Most subjects reported moderate photophobia for 2 to 3 days after SLT; only 1 received a
65 n, 7 on scale 1-10), conjunctival injection, photophobia, foreign body sensation, and tearing during
66 without headache and 20 each with interictal photophobia from migraine with or without visual aura.
67 g, for example, at 2 h post-dose, absence of photophobia in 19.5% and 12.5% of ubrogepant- and placeb
68 geminal nociceptive system may contribute to photophobia in individuals with chronic ocular surface p
69 lteration in processing of ipRGC signals for photophobia in migraine.
70 epartment complaining of pain, hyperemia and photophobia in the right eye following a HIFU applicatio
71 ractions that govern ocular surface pain and photophobia is critical for developing effective, precis
72                     Second only to headache, photophobia is the most debilitating symptom reported by
73         The disease presents with a triad of photophobia, loss of color vision and reduced central vi
74 utosomal recessive disorder characterized by photophobia, low visual acuity, nystagmus and a total in
75                Recent studies demonstrated a photophobia mechanism with modulation of nociceptive, co
76 17; 39%), followed by tearing (n = 10; 23%), photophobia (n = 6; 14%), itching (n = 4; 9%), swelling
77 e disorder characterized by color blindness, photophobia, nystagmus and severely reduced visual acuit
78 y alterations in sensory perception, such as photophobia or allodynia, which have in common an uncomf
79 he authors find an effect on the OAER due to photophobia or eye color.
80 s were headache (195 of 204 patients [95%]), photophobia or phonophobia (143 of 188 [76%]), and neck
81 effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours.
82  absence of most bothersome symptom (nausea, photophobia, or phonophobia).
83 chal rigidity, altered cutaneous sensations, photophobia, or visual disturbances.
84 consist of blurred vision, redness, tearing, photophobia, pain and foreign body sensation.
85 ing, foreign body sensation, eye discomfort, photophobia, pain), ocular discomfort score (ODS), and s
86                       Fifteen eyes (83%) had photophobia, pain, or both.
87 to understand better the neural substrate of photophobia paved a way to the development of different
88 s reported so far include: headaches, severe photophobia, persistent foreign body sensation, and migr
89 othersome migraine-associated symptom (among photophobia, phonophobia, and nausea) at 2 hours after t
90 bsence of symptoms associated with migraine (photophobia, phonophobia, and nausea) at 2 hours.
91 ache attacks, which are often accompanied by photophobia, phonophobia, nausea and vomiting.
92 ere pain freedom, pain relief, or absence of photophobia, phonophobia, or nausea at 2 h after treatme
93      A 34 year old male presented with pain, photophobia, redness and decreased vision in his right e
94 segment of the eye, characterized by intense photophobia, redness, watering eyes and itching due to a
95 characterized by reduced visual acuity, mild photophobia, reduced amplitude of the cone electroretino
96  with variable degrees of night blindness or photophobia, reduced visual acuity, high myopia, and nys
97      The visual acuity, subjective glare and photophobia reduction, anatomic outcome, and complicatio
98 ar-old child with cyst recurrence and severe photophobia requiring resection.
99  8% (n = 5) reported blurred near vision and photophobia, respectively, during year 3, compared with
100 ne crystal depth, contrast sensitivity (CS), photophobia score, and safety.
101 CCCS, IVCM score, corneal crystal depth, and photophobia score; however, local adverse effects and bl
102 a or vomiting, fever, weight loss, headache, photophobia, seizure, extremity weakness, or sensory dis
103 defects, cleft palate, extradural cysts, and photophobia, suggesting a defect in a gene with pleiotro
104                       FL-41 lenses modulated photophobia symptoms in some individuals with chronic oc
105 re, rescue medication use, key VKC symptoms (photophobia, tearing, itching, and mucous discharge), an
106 ion in mice as a surrogate for migraine-like photophobia to compare CGRP and PACAP and ask whether CG
107 ary measures include reduction in nausea and photophobia, use of rescue medication, relapse of headac
108 ptoms including nausea, unilateral location, photophobia, visual disturbance, and numbness.
109 t were during early infancy in all patients, photophobia was seen in patients with ALMS1 and CABP4, a
110                                Historically, photophobia was studied in patients and attempts to expl
111 ver, nausea/vomiting, malaise, headache, and photophobia were significantly associated with acute HIV
112                                   Nausea and photophobia were significantly reduced (P=.03 and P=.001
113       We have focused on the role of CGRP in photophobia, which is a common migraine symptom.
114 ich was unilateral in 14 (48%); 29 (74%) had photophobia, which was unilateral in 14 (48%); and 27 (6
115 ation revealed severe vision loss, pain, and photophobia, with signs indicative of corneal hyphal inf

 
Page Top